Severe leading to transplantation and death. Risk increased with > 2 weeks duration. Use only in life-threatening infections and in an inpatient facility. Should not be used when safer alternatives are available.
Monitoring data
Monitor LFTs in patients who develop signs/symptoms consistent with hepatitis. Consider discontinuing drug in patients who develop elevated LFTs.